Nour Heart INC
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersVienna, VA
US patents7
SAM.gov UEIZNSWMA88N9J5
CAGE code4JD73
Brands
First slideThird slideThis company sells these brands.
- early detection
- prevention
- according
- Nourin molecular biomarkers
- Cyclocreatine Phosphate
- myocardial ischemia
- ischemic heart disease
Named on the company’s own website, read JUL 29, 2026
Patents
7 US patents granted 2010–2023, 3 of them in the five years to SEP 2025.
Measurement 4Pharmaceuticals 2Organic fine chemistry 1
- Nourin gene-based RNA molecular network: novel early diagnostic and prognostic biomarkers for coronary artery disease, unstable angina, STEMI/NSTEMI and heart failureUS 11,761,966 · granted SEP 19, 2023
- Cyclocreatine phosphate: a novel bioenergetic therapy to prevent and treat ischemia-induced and aging-related cardiovascular and neurodegenerative diseasesUS 11,654,134 · granted MAY 23, 2023
- Autophagy-related nourin gene-based RNA network as early biomarkers for cardiac patientsUS 10,895,572 · granted JAN 19, 2021
- Methods to prevent and treat diseasesUS 8,288,350 · granted OCT 16, 2012
- Phosphagen synthesisUS 7,964,736 · granted JUN 21, 2011
Newest 5 shown · Granted to Nour Heart, INC. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Nour Heart INC | Vienna | VA | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.